retinal diseases
Sep 23, 2019
Boehringer Ingelheim ties up with Inflammasome Therapeutics
Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies for the patients with retinal diseases.The deal is about jointly developing three novel therapies for retinal diseases with the help of Inflamma...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
